The product will be manufactured at the company's Pithampur, Unit 3
facility, Lupin said in a filing to the BSE. The approval by the
United States Food and Drug Administration (USFDA) is to market its
generic Betamethasone Dipropionate ointment USP (augmented), 0.05 per
cent, it added.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-usfda-nod-to-market-skin-ointment/articleshow/72901066.cms
No comments:
Post a Comment